Abiozen’s CRO360™ division leverages a robust global site network to deliver trials that are scientifically rigorous, demographically inclusive, and regulatorily aligned. With over 300 affiliated research institutions and hospitals across North America, Europe, and the Asia-Pacific region, we ensure that clinical studies are conducted in diverse settings—strengthening data generalizability and increasing acceptance by global regulatory bodies. Our site strategy is built upon therapeutic specialization, historical performance, and regulatory landscape intelligence, enabling sponsors to achieve faster startup times and broader clinical impact.

We maintain strong alliances with Key Opinion Leaders (KOLs), clinical investigators, and institutional partners, fostering seamless coordination and elevated trial execution. These relationships enhance protocol adherence, reduce site activation timelines, and ensure consistent data capture across geographies. Our global footprint is modeled after best-in-class frameworks, including Thermo Fisher Patheon’s expansive site network, allowing us to support complex, multi-region trials with confidence.

Inclusivity is central to our operational ethos. We strategically target diverse patient populations across race, ethnicity, gender, and socioeconomic groups to produce more representative clinical data. This approach not only enhances scientific validity but also meets the growing expectations of regulatory agencies for equitable and inclusive research practices.

Whether managing rare disease trials in specialized academic centers or high-volume vaccine studies in metropolitan hospitals, Abiozen’s global infrastructure ensures operational agility, regulatory readiness, and real-world relevance across every therapeutic area.